dc.contributor
Institut Català de la Salut
dc.contributor
[Schettini F] Translational Genomics and Targeted Therapies in Solid Tumors Research Group, Barcelona, Spain. Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain. [Giuliano M] Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. [Lambertini M] Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy. Department of Medical Oncology, U.O.C Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. [Bartsch R] Division of Oncology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria. [Pinato DJ] Division of Cancer, Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK. Department of Translational Medicine, Università del Piemonte Orientale “A. Avogadro”, Novara, Italy. [Onesti CE] Clinical and Oncological Research Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy. [Cortes J] Oncology Department, IOB Institute of Oncology, Quiron Group, 08023 Madrid, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Schettini, Francesco
dc.contributor.author
Giuliano, Mario
dc.contributor.author
Bartsch, Rupert
dc.contributor.author
Pinato, David James
dc.contributor.author
Onesti, Concetta Elisa
dc.contributor.author
Cortés Castan, Javier
dc.contributor.author
Lambertini, Matteo
dc.date.accessioned
2025-10-25T05:38:52Z
dc.date.available
2025-10-25T05:38:52Z
dc.date.issued
2022-03-15T12:24:22Z
dc.date.issued
2022-03-15T12:24:22Z
dc.identifier
Schettini F, Giuliano M, Lambertini M, Bartsch R, Pinato DJ, Onesti CE, et al. Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers. 2021 Sep;13(17):4421.
dc.identifier
https://hdl.handle.net/11351/7184
dc.identifier
10.3390/cancers13174421
dc.identifier
000694139700001
dc.identifier.uri
http://hdl.handle.net/11351/7184
dc.description.abstract
Antraciclines; Càncer de mama; Receptor hormonal
dc.description.abstract
Antraciclinas; Cáncer de mama; Receptor hormonal
dc.description.abstract
Anthracyclines; Breast cancer; Hormone receptor
dc.description.abstract
Anthracyclines are among the most active chemotherapies (CT) in breast cancer (BC). However, cardiotoxicity is a risk and peculiar side effect that has been limiting their use in clinical practice, especially after the introduction of taxanes. Non-pegylated liposomal doxorubicin (NPLD) has been developed to optimize the toxicity profile induced by anthracyclines, while maintaining its unquestionable therapeutic index, thanks to its delivering characteristics that increase its diffusion in tumor tissues and reduce it in normal tissues. This feature allows NPLD to be safely administered beyond the standard doxorubicin maximum cumulative dose of 450–480 mg/m2. Following three pivotal first-line phase III trials in HER2-negative metastatic BC (MBC), this drug was finally approved in combination with cyclophosphamide in this specific setting. Given the increasing complexity of the therapeutic scenario of HER2-negative MBC, we have carefully revised the most updated literature on the topic and dissected the potential role of NPLD in the evolving therapeutic algorithms.
dc.description.abstract
This study was supported by Mednote, spin-off—University of Trieste, within the Mozart Program.
dc.format
application/pdf
dc.relation
Cancers;13(17)
dc.relation
https://doi.org/10.3390/cancers13174421
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Mama - Càncer - Tractament
dc.subject
Quimioteràpia combinada
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.title
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
